Tyrosine kinase inhibitorFDA-approvedFirst-line

BRAF/MEK Inhibitor Combination (Dabrafenib + Trametinib)

Generic name: dabrafenib + trametinib

How it works

Blocks BRAF and MEK, proteins involved in cell growth and division, which can help slow down cancer growth.

Cancer types

Melanoma— BRAF V600E or V600K mutation

Efficacy

Studies show that around 50% of patients with BRAF V600E or V600K mutation achieved an objective response, with a median overall survival of approximately 25.1 months.

Side effects

Moderate

Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.

This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.